Replies to post #13462 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

MNTA did change the terms of restricted-share awards for executive officers by extending the deadline; from the 1Q15 PR:

In 2011 and 2012 the Company granted broad-based performance stock awards that vested 50% upon approval of the M356 ANDA and 50% one year later. The awards were scheduled to expire March 28, 2015.

In March 2015, the Company amended the awards to extend the performance period to September 2015, but with share amounts that decreased monthly.

Since Glatopa approval came in April (the first month of the extension period), the awards were for the full amount in the original plan.